摘要
目的:评价中药联合靶向药物吉非替尼治疗非小细胞肺癌的疗效和安全性。方法:检索Pubmed数据库、中国期刊全文数据库、中国生物医学文献数据库、万方数据库、中文科技期刊数据库,纳入中药联合吉非替尼治疗非小细胞肺癌的随机对照试验为研究对象,根据Cochrane协作网质量评价标准提取资料,并采用Revman 5.20对治疗有效率、1年生存率、生活质量和不良反应等结局指标进行Meta分析。结果:共纳入11篇文献689例非小细胞肺癌患者。11项研究显示中药联合吉非替尼组治疗有效率、5项研究显示中药联合吉非替尼组生活质量改善率、2项研究显示中药联合吉非替尼组患者1年生存率,均高于单药吉非替尼组(P<0.05);9项研究显示中药联合吉非替尼组皮疹发生率、6项研究显示中药联合吉非替尼组腹泻发生率,均低于单药吉非替尼组(P<0.01)。结论:中药联合吉非替尼治疗非小细胞肺癌在有效率及1年生存率方面较单药吉非替尼存在优势,并能提高患者生活质量,减少不良反应。
Objective： To evaluate the efficacy and safety of traditional Chinese medicine（TCM） combined with gefitinib for non-small cell lung cancer（NSCLC）. Methods： The randomized controlled trials（RCTs） of TCM combined with gefitinib for NSCLC were searched in Pub Med, CNKI, CBM, Wanfang and VIP database. The Cochrane Handbook Scale was used to extract the data and outcomes such as efficacy, 1-year survival rates, quality of life（QOL） and adverse events were analyzed by Revman 5.0 software. Results： There were 11 RCTs and 689 cases of NSCLC included. The efficacy in 11 RCTs, QOL improvement in 5 RCTs and 1-year survival rates in 2 RCTs in TCM combined with gefitinib group were significantly higher than those in gefitinib alone group（P〈0.05）. The incidence of rash in 9 RCTs and incidence of diarrhea in 6 RCTs in TCM combined with gefitinib group were significantly lower than those in gefitinib alone group（P〈0.01）. Conclusion： The efficacy of TCM combined with gefitinib for NSCLC is superior to gefitinib alone with higher QOL, fewer adverse events and higher 1-year survival rates.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2015年第11期4163-4165,共3页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金项目(No.81273963)
广东省自然科学基金重点项目(No.S2012020010886)~~
关键词
非小细胞肺癌
中药
吉非替尼
随机对照试验
系统评价
Non-small cell lung cancer
Traditional Chinese medicine
Gefitinib
Randomized controlled trials
Systematic review
